Atıf İçin Kopyala
Beyaz S., Erecan E., MUTLU P., ÖZŞEKER Z. F.
EURASIAN JOURNAL OF PULMONOLOGY, cilt.24, sa.2, ss.85-94, 2022 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
24
Sayı:
2
-
Basım Tarihi:
2022
-
Doi Numarası:
10.14744/ejp.2022.9821
-
Dergi Adı:
EURASIAN JOURNAL OF PULMONOLOGY
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.85-94
-
Anahtar Kelimeler:
Asthma, biologic agents, COVID-19, dupilumab, mepolizumab, omalizumab, INFECTION, DISEASE, THERAPY, PATIENT, TMPRSS2, PEOPLE, ACE2
-
Çanakkale Onsekiz Mart Üniversitesi Adresli:
Evet
Özet
BACKGROUND AND AIM: Biologics can be used safely for patients with severe asthma during the coronavirus pandemic, but there is still a lack of information regarding their effects during SARS-CoV-2 infection. The aim of this study was to evaluate the impact of biologic therapies on the course of SARS-CoV-2 infection and to assess the outcome of COVID-19 for severe asthmatics in pandemic conditions.